A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Inclusion Criteria:

• BMI ≥27.0 kg/m2 to ≤50.0 kg/m2 at screening

• Type 2 diabetes mellitus (*T2DM) for at least 3 months before screening

• Glycated hemoglobin (HbA1c) value between ≥7.0% (53.0 mmol/mol) and ≤10.5% (91.3mmol/mol) at Screening and treated with stable therapy for at least 30 days prior toScreening/Visit 1 (diet and exercise alone or in combination with metforminmonotherapy and/or SGLT-2)

• Stable body weight (increase or decrease ≤5 kg) within 3 months prior to screening

Exclusion Criteria:

• Female who is lactating or who is pregnant

• Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2

• Fasting triglycerides ≥ 5.6 mmol/L (≥500 mg/dL)

• Poorly controlled hypertension

• History of stroke

• Significant cardiovascular disease including but not limited to unstable angina orvalvular heart disease or has a history of myocardial infarction, coronary arterybypass graft, percutaneous coronary artery re-vascularization, or congestive heartfailure

• Diagnosis of Type 1 diabetes (history of ketoacidosis, hyperosmolar state/coma, orany other types of diabetes except T2DM)

• History of acute or chronic pancreatitis

• Family or personal history of medullary thyroid carcinoma (MTC) or multipleendocrine neoplasia syndrome type 2 (MEN-2)

• History of significant active or unstable major depressive disorder (MDD) or othersevere psychiatric disorder within the last 2 years

• Relevant surgical history including all bariatric or weight loss surgeries

• SGLT2 inhibitors and/or metformin

• Had 1 or more episodes of hypoglycemia